Videos

Using biosimilars and generics as well as getting patients connected with manufacturer copay assistance or grant programs can reduce their out-of-pocket costs.

Panelists discuss how their institutions approach frontline treatment for transplant-eligible multiple myeloma patients, typically using a combination of novel agents like proteasome inhibitors and immunomodulatory drugs, followed by autologous stem cell transplantation and maintenance therapy, while considering factors such as patient characteristics and treatment response to guide therapy sequencing.

Panelists discuss how the current first-line treatment options for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) typically involve combination therapies including proteasome inhibitors, immunomodulatory drugs, and steroids.

Clayton Irvine, PharmD, MBA, MS, notes that although these options help to lower the cost of care, quick, widespread implementation remains difficult.

Rahul Banerjee, MD, FACP, discussed his presentation at the International Myeloma Society 2024 Annual Meeting on available T cell-directed therapies for myeloma treatment, including CAR T-cell therapies and bispecific antibodies.

Banerjee addressed factors to consider when selecting a regimen, the available treatments in this category, and their key differences.

Automation and artificial intelligence can also aid significantly in reducing time-consuming tasks and improving efficiency for pharmacists, allowing them more time with patients.

Although Madabhushi said there are emerging tools for clinical decision support, he said there is a greater need for tools further downstream in the post-diagnosis stages.

As the end of the DSCSA stabilization period approaches, Josh Bolin from the NABP provides an overview of what to expect.

Pharmacy students discuss a non-traditional learning assignment that used the social media platform, TikTok.

William Carroll, PharmD, network vice president of pharmacy at Hackensack Meridian Health, discusses his hopes for the new partnership.

Childhood immunization according to schedule can prevent serious illness.

Erin McConnell, PharmD, discuss the clinical decision-making process for choosing between statins, PSCK9 inhibitors, or newer agents like inclisiran.

Erin McConnell, PharmD, discusses the importance of effective cholesterol management for preventing heart disease.

Experts highlight how leveraging organizational scale, data analytics, and community partnerships can enable independent pharmacies to identify and address pharmacy deserts.

The discussion explores the frequency and impact of dose modifications due to adverse events, strategies for maintaining outcomes, monitoring protocols, and how these modifications affect long-term CLL therapy effectiveness and treatment decisions.

The discussion addresses when dose modifications are typically required in chronic lymphocytic leukemia treatment and identifies the most common reasons for these modifications.

As the end of this Congress approaches, the National Community Pharmacists Association is lobbying members to pass pharmacy benefit manager reforms.

The chief product and strategy officer at Linus Health is hopeful that pharmacists can be key players in the detection of mild cognitive impairment.

Jenni Zilka discusses the growing issue of "pharmacy deserts" and the need to maintain the financial viability of pharmacies.

The combination of amivantamab and lazertinib showed improved intracranial efficacy, progression-free survival, and overall survival for non-small cell lung cancer.

Pharmacy students discuss the value of collaborative, hands-on learning approaches that leverage technology and social media to enhance learning.

The discussion covers proactive strategies and interventions for managing adverse events before dose modification and explores supportive care measures for chronic lymphocytic leukemia treatments, including variations based on specific Bruton tyrosine kinase inhibitors.

The discussion explores the evolution of understanding adverse events (AEs) related to Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment and identifies the primary classwide AEs associated with these therapies.

The panel of pneumococcal vaccination experts offer their concluding insights and perspectives on the current landscape of pneumococcal vaccines.

Dr Humphreys discusses biosimilar copay programs.

Glenn Balasky discusses AI’s potential to change oncology care and optimize patient outcomes.

Fred Barton discusses the role of PBMs in making prescription drug decisions.

Tune into this episode of “Public Health Matters” to learn about the Unbiased Science podcast and how guest Jessica Steier, DrPH, PMP, aims to combat misinformation and disinformation, encouraging listeners to make evidence-based decisions.

Gwen Nichols, MD, discusses challenges associated with the limited access to CAR T therapy and the need to expand outpatient and community care for patients.